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Background: Angiotensin-Converting-Enzyme inhibitors (ACE-Is) and Angiotensin Receptors Blockers (ARBs) reduce the risk of cardiovascular (CV) 
events in patients with left ventricular systolic dysfunction (LVSD). However, it is debated if ARBs do in patients with or at high CV risk without LVSD. 
We investigated the effects of each by a meta-analysis of available clinical trials.
Methods: All randomized trials assessing an ARB or an ACE-I versus placebo in patients without heart failure or uncontrolled hypertension were 
included. Overall estimates of effect were calculated with fixed-effects or random effects model. The influence of baseline patients’ characteristics, 
CV risk profile, blood pressure change, follow up and trial quality was explored.
Results: Ten trials were included with 76,908 participants, with a mean age of 64 (±3) years, of whom 33% women and with approximately equal 
numbers assigned either to an ARB or an ACE-I or to placebo. Mean follow-up was 3.9 (±1.3) years. Compared to placebo, ACE-Is reduced the risk 
of CV morbidity and mortality [composite outcome Odds Ratio (OR) 0.79, 95% Confidence Interval (CI) 0.75 to 0.83, p<0.0001; all-cause mortality 
OR 0.88, 95% CI 0.82 to 0.95, p=0.001; CV death OR 0.84, 95% CI 0.76 to 0.92, p<0.0001; myocardial infarction OR 0.83, 95% CI 0.74 to 0.94, 
p=0.003; stroke or TIA OR 0.74, 95% CI 0.66 to 0.82, p<0.0001]. However, ARBs generally did not (all-cause mortality OR 1.00, 95% CI 0.93 to 
1.09, p=0.83; CV death OR 0.99, 95% CI 0.8 to 1.11, p=0.81; myocardial infarction OR 0.93, 95% CI 0.84 to 1.04; p=0.15). Nevertheless, ARBs 
reduced the risk of stroke or TIA (OR 0.92, 95% CI 0.84 to 1.00; p=0.04) and of composite outcome (OR 0.93, 95% CI 0.88 to 0.99, p=0.02). 
Baseline patients’ characteristics, CV risk profile, blood pressure modification and follow up did not substantially affect these results.
Conclusions: In contrast to ACE-Is, ARBs did not reduce the risk of many major CV end-points in patients without heart failure. Although, these 
trials did not directly compare ACE-Is and ARBs, ARBs may be less effective in reducing CV events in patients with or at risk of CV disease.
